Company intelligence / Profile preview
SciFluor Life Sciences
Boston / Cambridge, Massachusetts, United Statesscifluor.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
SciFluor developed a pipeline based on proprietary fluorine chemistry to create differentiated small molecule drugs. Lead programs included SF0034 for epilepsy/tinnitus and SF0166 for retinal diseases. As of the last available updates, SF0166 had entered clinical trials for AMD/DME, while SF0034 was advancing toward the clinic with strong preclinical data. No recent clinical results are available.
- Therapeutic areas
- OphthalmologyNeurology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on SciFluor Life Sciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SciFluor Life Sciences.